Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02008942 · ClinicalTrials.gov registry record · Phase 3
Pharmacodynamic Evaluation of PL2200 Versus Enteric-Coated Aspirin in Diabetic Patients
A Phase 3 study of Diabetes Mellitus, Type 2, sponsored by PLx Pharma.
- Completed
- Registry status
- Phase 3
- Development phase
- 57
- Enrollment target
- 3
- Study locations
NCT02008942 is a Phase 3 study of Diabetes Mellitus, Type 2 that has completed, run by PLx Pharma. The registered enrollment target is 57 participants, below the 4,485-participant average among 348 other Diabetes Mellitus, Type 2 trials with a reported enrollment target (99% lower). The trial reports 3 study locations across 3 states.
The verdict
NCT02008942, a Phase 3 study of Diabetes Mellitus, Type 2, has completed, sponsored by PLx Pharma.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 57 participants
- Enrollment target
- 3
- Study locations
Study Summary
This study will determine if aspirin from PL2200, an investigational product, gets into the blood stream as quickly as enteric coated aspirin, and to test whether PL2200 is able to prevent blood clots as effectively as enteric coated aspirin, when administered to patients with diabetes
Conditions Studied
Interventions
- DRUG PL2200 Aspirin Capsules
- DRUG Enteric-coated aspirin caplets
Study Locations (3)
Florida
- Miami Research Associates - Miami
Kansas
- PRA Clinical Pharmacology Center - Lenexa
Ohio
- Medpace Clinical Pharmacology - Cincinnati
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 57 participants |
| Start Date | 2014-01 |
| Est. Completion | 2014-04 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02008942
The ClinicalTrials.gov registry entry for NCT02008942 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 57 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 4,485-participant average among 348 other Diabetes Mellitus, Type 2 trials with a reported enrollment target (99% lower). The listed sponsor is PLx Pharma, which has 9 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Diabetes Mellitus, Type 2 appearing as the primary indexed condition, and to 2 interventions - of which PL2200 Aspirin Capsules is the first listed.
NCT02008942 reports 3 study locations spanning 3 distinct geographic areas - top geographies include Florida, Kansas, Ohio.
Frequently Asked Questions
What is clinical trial NCT02008942 about?
NCT02008942 is a clinical study titled "Pharmacodynamic Evaluation of PL2200 Versus Enteric-Coated Aspirin in Diabetic Patients". This study will determine if aspirin from PL2200, an investigational product, gets into the blood stream as quickly as enteric coated aspirin, and to test whether PL2200 is able to prevent blood clots as effectively as enteric coated aspirin, when administered to patients with diabetes
What is the current status of trial NCT02008942?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 57 participants. The study started on 2014-01. Estimated completion is 2014-04.
What conditions does trial NCT02008942 study?
This clinical trial studies the following conditions: Diabetes Mellitus, Type 2.
What interventions are being tested in trial NCT02008942?
The interventions under investigation include: PL2200 Aspirin Capsules (DRUG), Enteric-coated aspirin caplets (DRUG).
Who is sponsoring clinical trial NCT02008942?
This trial is sponsored by PLx Pharma, which has 9 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02008942 being conducted?
This trial has 3 study locations across Florida, Kansas, Ohio. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Diabetes Mellitus, Type 2
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
EASi-PROTKT™ - A Study to Test Vicadrostat (BI 690517) Taken Together With Empagliflozin in People With Type 2 Diabetes, High Blood Pressure, and Cardiovascular Disease
RECRUITING · Phase 3
-
Effect of Retatrutide Compared With Semaglutide in Adult Participants With Type 2 Diabetes and Inadequate Glycemic Control With Metformin With or Without SGLT2 Inhibitor (TRANSCEND-T2D-2)
ACTIVE NOT RECRUITING · Phase 3
-
A Research Study to Look at How Semaglutide Compared to Placebo Affects Diabetic Eye Disease in People With Type 2 Diabetes
ACTIVE NOT RECRUITING · Phase 3
-
A Research Study to See How Much CagriSema Lowers Blood Sugar and Body Weight Compared to Tirzepatide in People With Type 2 Diabetes Treated With Metformin, SGLT2 Inhibitor or Both
ACTIVE NOT RECRUITING · Phase 3
-
A Study to Test Whether Survodutide (BI 456906) Helps People Living With Overweight or Obesity Who Also Have Diabetes to Lose Weight
ACTIVE NOT RECRUITING · Phase 3
-
A Research Study to Find Out How Semaglutide Works in the Kidneys Compared to Placebo, in People With Type 2 Diabetes and Chronic Kidney Disease (the REMODEL Trial)
COMPLETED · Phase 3
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.